160 GSK Annual Report 2018 Notes to the financial statements continued 12.
Finance expense 2018 2017 2016 m m m Finance expense arising on: Financial liabilities at amortised cost 677 698 671 Derivatives at fair value through profit or loss 38 22 30 Net losses arising from: Financial instruments mandatorily measured at fair value through profit or loss 3 4 3 Reclassification of hedges from other comprehensive income 2 1 Unwinding of discounts on provisions 15 16 16 Other finance expense 69 6 15 798 734 736 All derivatives accounted for at fair value through profit or loss, other than designated and effective hedging instruments see Note 42, Financial instruments and related disclosures, are classified as held-for-trading financial instruments.
Interest expense arising on derivatives at fair value through profit or loss relates to swap interest expense.
Other finance expense in 2018 includes a 39 million charge 2017 24 million credit for interest relating to historical income tax settlements.
Associates and joint ventures The Groups share of after tax profits and losses of associates and joint ventures is set out below: 2018 2017 2016 m m m Share of after tax profits of associates 28 16 9 Share of after tax profits losses of joint ventures 3 3 4 31 13 5 At 31 December 2018, the Group held one significant associate, Innoviva, Inc. Summarised income statement information in respect of Innoviva is set out below for the periods in which the Group accounted for its investment in Innoviva as an associate.
The Groups 2018 share of after tax profits of associates and other comprehensive income includes a profit of 33 million and other comprehensive income of nil in respect of Innoviva.
2018 2017 2016 m m m Turnover 183 165 98 Profit after taxation 134 103 44 Other comprehensive income Total comprehensive income 134 103 44 The results of Innoviva included in the summarised income statement information above represent the estimated earnings of Innoviva in the relevant periods, based on publicly available information.
Innovivas turnover is from royalty income from GSK in relation to Relvar Breo Ellipta, Anoro Ellipta and Trelegy Ellipta sales.
Aggregated financial information in respect of GSKs share of other associated undertakings and joint ventures is set out below: 2018 2017 2016 m m m Share of turnover 242 252 133 Share of after tax losses profits 2 5 1 Share of other comprehensive income Share of total comprehensive expense income 2 5 1 The Groups sales to associates and joint ventures were 43 million in 2018 2017 41 million: 2016 43 million.
